Peptide derived from stromal cell-derived factor 1δ enhances the in vitro expression of osteogenic proteins via bone marrow stromal cell differentiation and promotes bone formation in in vivo models

Biomater Sci. 2023 Sep 26;11(19):6587-6599. doi: 10.1039/d3bm00798g.

Abstract

Mesenchymal stem cells (MSCs) rely on chemokines and chemokine receptors to execute their biological and physiological functions. Stromal cell-derived factor-1 (SDF-1) is upregulated in injury sites, where it acts as a chemotactic agent, attracting CXCR4-expressing MSCs, which play a pivotal role in the healing and regeneration of tissue throughout the body. Furthermore, SDF-1 expression has been observed in regions experiencing inflammation-induced bone destruction and fracture sites. In this study, we identified a novel peptide called bone-forming peptide-5 (BFP-5), derived from SDF-1δ, which can promote the osteogenesis of MSCs as well as bone formation and healing. Multipotent bone marrow stromal cells treated with BFP-5 showed enhanced alizarin red S staining and higher alkaline phosphatase (ALP) activity. Moreover, ALP and osterix proteins were more abundantly expressed when cells were treated with BFP-5 than SDF-1α. Histology and microcomputed tomography data at 12 weeks demonstrated that both rabbit and goat models transplanted with polycaprolactone (PCL) scaffolds coated with BFP-5 showed significantly greater bone formation than animals transplanted with PCL scaffolds alone. These findings suggest that BFP-5 could be useful in the development of related therapies for conditions associated with bones.

MeSH terms

  • Animals
  • Bone Marrow Cells
  • Bone Morphogenetic Proteins / metabolism
  • Cell Differentiation
  • Chemokine CXCL12 / metabolism
  • Chemokine CXCL12 / pharmacology
  • Mesenchymal Stem Cells*
  • Osteogenesis*
  • Rabbits
  • Stromal Cells / metabolism
  • X-Ray Microtomography

Substances

  • Bone Morphogenetic Proteins
  • Chemokine CXCL12